Opinion|Videos|January 6, 2025
Patient-Centered Approaches in EGFR-Mutated NSCLC
Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Advertisement
Video content above is prompted by the following:
- From your perspective, how have oral and subcutaneous therapies changed the quality of life for patients with EGFR-mutated NSCLC?
- What benefits have patients shared with you about their experiences with these newer administration routes?
- Looking ahead in EGFR-mutated NSCLC treatment, what developments are you most excited about?
- Please highlight any trials, novel agents, or combinations you find promising.
- How do you see the role of the multidisciplinary care team evolving as these therapies advance?
- As patients take more charge of their care, how do you see the role of patient empowerment and self-management evolving?
- What strategies have you found effective in supporting patients to take a more active role in their treatment journey?
- How do you balance the benefits of home-based care with ensuring patients feel supported and connected to their health care team?
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5